VC-backed Arsanis goes public
Waltham, Massachusetts-based Arsanis Inc, a developer of targeted monoclonal antibodies for treating serious infectious diseases, has raised $40 million for its IPO after pricing its IPO of four million shares at $10 per share. The stock began trading November 16, 2017 on the NASDAQ under the ticker symbol "ASNS." Citigroup, Cowen and Company and Piper Jaffray & Co are the lead underwriters. And, in a separate transaction, New Enterprise Associates has agreed to provide $20 million to Arsanis in a private placement. Arsanis' pre-IPO backers include the Bill & Melinda Gates Foundation, GV, Alexandria Venture Investments, OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation.
